Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Gorf79on Apr 23, 2022 11:13am
197 Views
Post# 34626154

RE:Share Price Matters!

RE:Share Price Matters!Some further analysis: With the caveat that some reasonable assumptions have been made where inputs are not available and or market penetration figures are variable. A further caveat is that I have never reviewed an analyst report and I have no idea what his own valuation model looks like.

Lets combine my NPV with that of the analyst using his $1.20 share price discounted back a full 12 months with an IRR of 11% without a financial calculator and in  its most basic valuation calculation to determine an NPV.

Analyst Current NPV of roughly $1.07/share

My determined NPV (using some assumptions) - $3.46/share

Avererage Current SP - $2.26 share assuming a 30% probability of success

If company could achieve one third of this valuation prior to the next dilutive raise it would reduce dilution substantially. You can figure out the number. It’s your money.

Share Price Matters And Share Price First
<< Previous
Bullboard Posts
Next >>